Navtemadlin
Non Small Cell Lung Cancer
Kartos Therapeutics, Inc.Phase 1/2Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 65/ 100
Competitive context
203 Active assets in the Non Small Cell Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Vinorelbine Intergroupe Francophone de Cancerologie Thoracique | Phase 4 | BB |
Osimertinib Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 4 | BB |
Pyrotinib CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 4 | BB |
Nivolumab Fred Hutchinson Cancer Center | Phase 4 | BB |
Tislelizumab CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 4 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →